Skip to main content

Ankylosing Spondylitis

Rheumatology Consultant
Johan K. Wallman, MD, PhD, from Lund University, answers our questions about his research on the prevalence of gut symptoms meeting criteria for irritable bowel syndrome (IBS) among patients with axial spondyloarthritis compared with a control group.
Rheumatology Consultant
Authors of the MEASURE 3 study have shared their end‐of‐study 3‐year efficacy and safety results of secukinumab, 150 mg and 300 mg, among patients with active ankylosing spondylitis. Find out what the researchers determined.
Rheumatology Consultant
Jean Liew, MD, from the University of Washington, answers our questions about the relationship between cardiovascular risk and nonsteroidal anti-inflammatory drug use in the management of ankylosing spondylitis.
Rheumatology Consultant
David M. Spalding, MD, from the University of Alabama, discusses psychological health among patients with ankylosing spondylitis, the role of the rheumatologist in controlling disease to ensure better psychological health, and more,
Rheumatology Consultant
The ACR, SAA, and SPARTAN released an updated guideline for the management of AS and axial SpA that provides an overview of new treatment options and the use of imaging.
Back to Top